Advances in Multiple Sclerosis and Experimental Demyelinating Diseases
Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.
Mehr anzeigenSofort verfügbar, Lieferzeit: 1-3 Tage
Nur noch 1 Artikel verfügbar!
Weitere Infos zum Zustand
29,90 €
Preise inkl. MwSt. zzgl. Versandkosten
14 Tage Zufriedenheitsgarantie
Risikofrei bestellen
Geprüfte Gebrauchtware
Einzeln geprüft
Produktinformationen "Advances in Multiple Sclerosis and Experimental Demyelinating Diseases"
Anmelden
Versandkostenfrei ab 29 €
14 Tage Rückgaberecht - Kein Risiko
Geprüfte Gebrauchtware